Prevalence of Neurological Symptoms Associated with COVID-19

Authors: Syed Hassan Tanvir Ramzi, Ubaidullah Ansari, Sana Manzoor, Namal Ilyas, Nabeel Ahmed

Abstract:

To better understand the prevalence of neurological symptoms associated with COVID-19, several factors, such as age, gender, and comorbidity, are explored to create a more holistic understanding of the impact of COVID-19. After meeting inclusion and exclusion criteria, 111 patients admitted to Ibne Sina Hospital were recruited between October 2021 and February 2022. A descriptive statistical analysis was conducted to summarize patients most often encountered signs and symptoms concerning the above parameters. Out of 111 patients, a significant proportion of symptoms occurred in patients aged 40-60 years, with Dysgeusia being the most widespread (75.5%), followed by Encephalitis (45.9%), Guillain Barre Syndrome (GBS) (28.8%), Encephalopathy (18.9%), and Ischemic Stroke (6.3%). These were most prevalent in hypertensive individuals (46%) and Diabetes Mellitus (31%). In asthmatic individuals, they are the least prevalent (10.8%). Despite the predominance of neurological manifestations, the present scientific literature cannot demonstrate a definitive causal association between the symptoms and the virus. This study carefully ensures a link between age, gender, and comorbidity, along with the prevalence of neurological manifestations of COVID-19. For a comprehensive treatment plan, a holistic understanding of symptoms is critical.

Keywords: COVID-19, neurological associations, GBS, encephalopathy, encephalitis, dysgeusia, stroke.

References:

[1] Weekly epidemiological update on COVID-19 - 27 April 2022. www.who.int.
[2] Niazkar HR, Zibaee B, Nasimi A, Bahri N. The neurological manifestations of COVID-19: a review article. Neurological Sciences. 2020 Jun 1.
[3] Wang H-Y, Li X-L, Yan Z-R, Sun X-P, Han J, Zhang B-W. Potential neurological symptoms of COVID-19. Therapeutic Advances in Neurological Disorders. 2020 Jan;13:175628642091783.
[4] Mao L, Wang M, Chen S, He Q, Chang J, Hong C, et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study. 2020 Feb 25.
[5] Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain, Behavior, and Immunity. 2020 Mar 30;87:18－22.
[6] Rashedi J, Mahdavi Poor B, Asgharzadeh V, Pourostadi M, Samadi Kafil H, Vegari A, et al. Risk Factors for COVID-19. Le Infezioni in Medicina. 2020 Dec 1;28(4):469–74.
[7] Martines RB, Ritter JM, Matkovic E, Gary J, Bollweg BC, Bullock H, et al. Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States. Emerging Infectious Diseases. 2020 Sep;26(9).
[8] Allado E, Poussel M, Valentin S, Kimmoun A, Levy B, Nguyen DT, et al. The Fundamentals of Respiratory Physiology to Manage the COVID-19 Pandemic: An Overview. Frontiers in Physiology. 2021 Feb 18;11.
[9] Xydakis MS, Dehgani-Mobaraki P, Holbrook EH, Geisthoff UW, Bauer C, Hautefort C, et al. Smell and taste dysfunction in patients with COVID-19. The Lancet Infectious Diseases. 2020 Apr.
[10] Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure of COVID‐19 patients. Journal of medical virology. 2020 Jun;92(6):552-5.
[11] Desforges M, Le Coupanec A, Brison É, Meessen-Pinard M, Talbot PJ. Neuroinvasive and Neurotropic Human Respiratory Coronaviruses: Potential Neurovirulent Agents in Humans. Infectious Diseases and Nanomedicine I .2014 Mar 12;807:75–96.
[12] Kuy S, Tsai R, Bhatt J, Chu QD, Gandhi P, Gupta R, et al. Focusing on Vulnerable Populations During COVID-19. Academic Medicine. 2020 Jul 14;95(11).
[13] Kortela E, Kirjavainen V, Ahava MJ, Jokiranta ST, But A, Lindahl A, et al. Real-life clinical sensitivity of SARS-CoV-2 RT-PCR test in symptomatic patients. Ricci S, editor. PLOS ONE. 2021 May 21;16(5):e0251661.
[14] Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020 Jul 8;143(10).
[15] Neurological manifestations and COVID-19: Experiences from a tertiary care center at the Frontline. Journal of the Neurological Sciences. 2020 Aug 15 (cited 2020 Nov 19);415:116969.
[16] Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurology. 2020 Apr 10;
[17] Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic Features in Severe SARS-CoV-2 Infection. New England Journal of Medicine. 2020 Apr 15;
[18] Lewis A, Frontera J, Placantonakis DG, Lighter J, Galetta S, Balcer L, et al. Cerebrospinal fluid in COVID-19: A systematic review of the literature. Journal of the Neurological Sciences. 2021 Feb;421:117316.
[19] Tandon M, Kataria S, Patel J, Mehta TR, Daimee M, Patel V, et al. A Comprehensive Systematic Review of CSF analysis that defines Neurological Manifestations of COVID-19. International Journal of Infectious Diseases. 2021 Mar;104:390–7.
[20] Basu D, Chavda VP, Mehta AA. Therapeutics for COVID-19 and post COVID-19 complications: An update. Current Research in Pharmacology and Drug Discovery. 2022;3:100086.
[21] Karadaş Ö, Öztürk B, Sonkaya AR. A prospective clinical study of detailed neurological manifestations in patients with COVID-19. Neurological Sciences. 2020 Jun 25.
[22] Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurology. 2020 Apr 10.
[23] Koh JS, De Silva DA, Quek AML, Chiew HJ, Tu TM, Seet CYH, et al. Neurology of COVID-19 in Singapore. Journal of the Neurological Sciences. 2020 Nov;418:117118.
[24] Jakhmola S, Indari O, Baral B, Kashyap D, Varshney N, Das A, et al. Comorbidity Assessment Is Essential During COVID-19 Treatment. Frontiers in Physiology. 2020 Aug 4;11.
[25] Kumar M, Thakur AK. Neurological manifestations and comorbidity associated with COVID-19: an overview. Neurological Sciences. 2020 Oct 14.